Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accounts Payables (2018 - 2025)

Historic Accounts Payables for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $12.7 million.

  • Bicycle Therapeutics' Accounts Payables rose 12143.86% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 12143.86%. This contributed to the annual value of $15.8 million for FY2024, which is 2101.92% up from last year.
  • Bicycle Therapeutics' Accounts Payables amounted to $12.7 million in Q3 2025, which was up 12143.86% from $18.3 million recorded in Q2 2025.
  • Bicycle Therapeutics' Accounts Payables' 5-year high stood at $18.3 million during Q2 2025, with a 5-year trough of $996000.0 in Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $6.5 million (2022), whereas its average is $7.3 million.
  • As far as peak fluctuations go, Bicycle Therapeutics' Accounts Payables crashed by 7753.72% in 2021, and later soared by 30150.6% in 2022.
  • Over the past 5 years, Bicycle Therapeutics' Accounts Payables (Quarter) stood at $2.7 million in 2021, then skyrocketed by 137.85% to $6.5 million in 2022, then skyrocketed by 101.64% to $13.0 million in 2023, then increased by 21.02% to $15.8 million in 2024, then decreased by 19.88% to $12.7 million in 2025.
  • Its Accounts Payables stands at $12.7 million for Q3 2025, versus $18.3 million for Q2 2025 and $11.1 million for Q1 2025.